Tert-Butylamine → N1-tert-butyl-N4-(4-chloro-3-(pyridin-2-yl)phenyl)terephthalamide

HRID 633043Notes

Reaction equation

HRID 633043 reaction equation
[Cl:1][C:2]1[CH:7]=[CH:6][C:5]([NH:8][C:9]([C:11]2[CH:19]=[CH:18][C:14]([C:15](O)=[O:16])=[CH:13][CH:12]=2)=[O:10])=[CH:4][C:3]=1[C:20]1[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=1.[C:26]([NH2:30])([CH3:29])([CH3:28])[CH3:27]>>[C:26]([NH:30][C:15](=[O:16])[C:14]1[CH:18]=[CH:19][C:11]([C:9]([NH:8][C:5]2[CH:6]=[CH:7][C:2]([Cl:1])=[C:3]([C:20]3[CH:25]=[CH:24][CH:23]=[CH:22][N:21]=3)[CH:4]=2)=[O:10])=[CH:12][CH:13]=1)([CH3:29])([CH3:28])[CH3:27]

Participants

3

Reactant 2

HCID 6385Tert-ButylamineHCID 668778874-(4-Chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid

Product 1

HCID 58614838N1-tert-butyl-N4-(4-chloro-3-(pyridin-2-yl)phenyl)terephthalamide

Procedure

50 mg of 4-(4-chloro-3-(pyridin-2-yl)phenylcarbamoyl)benzoic acid was coupled to tert-butylamine via Procedure G. The product was purified on reverse phase HPLC to yield N1-tert-butyl-N4-(4-chloro-3-(pyridin-2-yl)phenyl)terephthalamide. MS (Q1) 408 (M)+.

Workup

  1. customThe product was purified on reverse phase HPLC

Sources & evidence

ORD record
ord-40ec899668a3436b8e5ef5b38dd4aef9
Source dataset
uspto-grants-2016_04
Patent number
US09321761B2

Reaction notes

Loading…